Cellebrite DI (CLBT) Current Deferred Revenue (2020 - 2025)

Cellebrite DI's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $327.1 million for Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 24.75% year-over-year to $327.1 million in Q4 2025; TTM through Dec 2025 was $327.1 million, a 24.75% increase from a year earlier, with the FY2025 full-year figure at $327.1 million, up 24.75% from the prior year.
• Current Deferred Revenue climbed to $327.1 million in Q4 2025 per CLBT's latest filing, from $239.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $327.1 million in Q4 2025 and bottomed at $115.0 million in Q3 2021.
• The 5-year median for Current Deferred Revenue is $185.0 million (2024), against an average of $190.4 million.
• Across the five-year window, Current Deferred Revenue jumped 34.06% in 2023 and climbed 7.99% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $159.4 million in 2021, then gained by 22.25% to $194.9 million in 2022, then advanced by 24.6% to $242.8 million in 2023, then increased by 7.99% to $262.2 million in 2024, then rose by 24.75% to $327.1 million in 2025.
• Per Business Quant, the three latest CLBT Current Deferred Revenue figures stand at $327.1 million (Q4 2025), $239.7 million (Q3 2025), and $227.2 million (Q2 2025).